Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

Similar articles for PubMed (Select 23536226)

1.

Acute cytotoxic effects of photoimmunotherapy assessed by 18F-FDG PET.

Sano K, Mitsunaga M, Nakajima T, Choyke PL, Kobayashi H.

J Nucl Med. 2013 May;54(5):770-5. doi: 10.2967/jnumed.112.112110. Epub 2013 Mar 27.

2.

Real-time monitoring of in vivo acute necrotic cancer cell death induced by near infrared photoimmunotherapy using fluorescence lifetime imaging.

Nakajima T, Sano K, Mitsunaga M, Choyke PL, Kobayashi H.

Cancer Res. 2012 Sep 15;72(18):4622-8. doi: 10.1158/0008-5472.CAN-12-1298. Epub 2012 Jul 16.

3.

Photoimmunotherapy targeting prostate-specific membrane antigen: are antibody fragments as effective as antibodies?

Watanabe R, Hanaoka H, Sato K, Nagaya T, Harada T, Mitsunaga M, Kim I, Paik CH, Wu AM, Choyke PL, Kobayashi H.

J Nucl Med. 2015 Jan;56(1):140-4. doi: 10.2967/jnumed.114.149526. Epub 2014 Dec 11.

PMID:
25500827
4.

Dynamic fluorescent imaging with indocyanine green for monitoring the therapeutic effects of photoimmunotherapy.

Ali T, Nakajima T, Sano K, Sato K, Choyke PL, Kobayashi H.

Contrast Media Mol Imaging. 2014 Jul-Aug;9(4):276-82. doi: 10.1002/cmmi.1570.

5.

(18)F-alfatide II and (18)F-FDG dual-tracer dynamic PET for parametric, early prediction of tumor response to therapy.

Guo J, Guo N, Lang L, Kiesewetter DO, Xie Q, Li Q, Eden HS, Niu G, Chen X.

J Nucl Med. 2014 Jan;55(1):154-60. doi: 10.2967/jnumed.113.122069. Epub 2013 Nov 14.

6.

Monitoring therapy with MEK inhibitor U0126 in a novel Wilms tumor model in Wt1 knockout Igf2 transgenic mice using 18F-FDG PET with dual-contrast enhanced CT and MRI: early metabolic response without inhibition of tumor growth.

Flores LG 2nd, Yeh HH, Soghomonyan S, Young D, Bankson J, Hu Q, Alauddin M, Huff V, Gelovani JG.

Mol Imaging Biol. 2013 Apr;15(2):175-85. doi: 10.1007/s11307-012-0588-5.

7.

The reverse Warburg effect and 18F-FDG uptake in non-small cell lung cancer A549 in mice: a pilot study.

Zhang G, Li J, Wang X, Ma Y, Yin X, Wang F, Zheng H, Duan X, Postel GC, Li XF.

J Nucl Med. 2015 Apr;56(4):607-12. doi: 10.2967/jnumed.114.148254. Epub 2015 Feb 26.

PMID:
25722447
8.

Photoimmunotherapy: comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor.

Sato K, Watanabe R, Hanaoka H, Harada T, Nakajima T, Kim I, Paik CH, Choyke PL, Kobayashi H.

Mol Oncol. 2014 May;8(3):620-32. doi: 10.1016/j.molonc.2014.01.006. Epub 2014 Jan 22.

9.

18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.

Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, Satyamurthy N, Schiepers C, Cloughesy T.

J Nucl Med. 2006 Jun;47(6):904-11.

10.

Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy.

Mitsunaga M, Nakajima T, Sano K, Kramer-Marek G, Choyke PL, Kobayashi H.

BMC Cancer. 2012 Aug 8;12:345. doi: 10.1186/1471-2407-12-345.

11.

[18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner.

Graf N, Herrmann K, Numberger B, Zwisler D, Aichler M, Feuchtinger A, Schuster T, Wester HJ, Senekowitsch-Schmidtke R, Peschel C, Schwaiger M, Keller U, Dechow T, Buck AK.

Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):34-43. doi: 10.1007/s00259-012-2255-0. Epub 2012 Oct 5.

PMID:
23053327
12.

[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.

Ma WW, Jacene H, Song D, Vilardell F, Messersmith WA, Laheru D, Wahl R, Endres C, Jimeno A, Pomper MG, Hidalgo M.

J Clin Oncol. 2009 Jun 1;27(16):2697-704. doi: 10.1200/JCO.2008.18.8383. Epub 2009 Apr 20.

13.

Near-infrared theranostic photoimmunotherapy (PIT): repeated exposure of light enhances the effect of immunoconjugate.

Mitsunaga M, Nakajima T, Sano K, Choyke PL, Kobayashi H.

Bioconjug Chem. 2012 Mar 21;23(3):604-9. doi: 10.1021/bc200648m. Epub 2012 Mar 8.

14.

Metformin--an adjunct antineoplastic therapy--divergently modulates tumor metabolism and proliferation, interfering with early response prediction by 18F-FDG PET imaging.

Habibollahi P, van den Berg NS, Kuruppu D, Loda M, Mahmood U.

J Nucl Med. 2013 Feb;54(2):252-8. doi: 10.2967/jnumed.112.107011.

15.

The effect of photoimmunotherapy followed by liposomal daunorubicin in a mixed tumor model: a demonstration of the super-enhanced permeability and retention effect after photoimmunotherapy.

Sano K, Nakajima T, Choyke PL, Kobayashi H.

Mol Cancer Ther. 2014 Feb;13(2):426-32. doi: 10.1158/1535-7163.MCT-13-0633. Epub 2013 Dec 19.

16.

Apoptosis imaging probe predicts early chemotherapy response in preclinical models: A comparative study with 18F-FDG PET.

Song S, Xiong C, Lu W, Ku G, Huang G, Li C.

J Nucl Med. 2013 Jan;54(1):104-10. doi: 10.2967/jnumed.112.109397.

17.

18F-FDG PET and MR imaging associations across a spectrum of pediatric brain tumors: a report from the pediatric brain tumor consortium.

Zukotynski K, Fahey F, Kocak M, Kun L, Boyett J, Fouladi M, Vajapeyam S, Treves T, Poussaint TY.

J Nucl Med. 2014 Sep;55(9):1473-80. doi: 10.2967/jnumed.114.139626. Epub 2014 Jul 28.

18.

Impact of animal handling on the results of 18F-FDG PET studies in mice.

Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D, Phelps ME, Weber WA.

J Nucl Med. 2006 Jun;47(6):999-1006.

19.

Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.

Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH.

J Nucl Med. 2005 Jun;46(6):945-52.

20.

111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model.

van Dijk LK, Boerman OC, Franssen GM, Kaanders JH, Bussink J.

J Nucl Med. 2015 Feb;56(2):287-92. doi: 10.2967/jnumed.114.148296. Epub 2014 Dec 31.

PMID:
25552666
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk